Adagene, Inc. (ADAG)

NASDAQ: ADAG · IEX Real-Time Price · USD
8.19
-0.34 (-4.04%)
At close: Jan 14, 2022 4:00 PM
7.82
-0.37 (-4.46%)
After-hours:Jan 14, 2022 5:39 PM EST
Market Cap356.68M
Revenue (ttm)700,913
Net Income (ttm)-42.65M
Shares Out43.58M
EPS (ttm)-2.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,154
Open8.15
Previous Close8.53
Day's Range7.65 - 8.45
52-Week Range7.00 - 31.83
Betan/a
AnalystsBuy
Price Target31.64 (+286.6%)
Earnings Daten/a

About ADAG

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of variou...

IndustryBiotechnology
IPO DateFeb 9, 2021
Employees198
Stock ExchangeNASDAQ
Ticker SymbolADAG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Adagene stock is "Buy." The 12-month stock price forecast is 31.64, which is an increase of 286.56% from the latest price.

Price Target
$31.64
(286.56% upside)
Analyst Consensus: Buy

News

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG10...

Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium Clinic...

3 days ago - GlobeNewsWire

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Cand...

- Successful nomination of lead SAFEbody candidates triggers milestone payment -

3 weeks ago - GlobeNewsWire

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a ...

- Posters presented at the 63 rd American Society of Hematology Annual Meeting -

1 month ago - GlobeNewsWire

Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial

Adagene Inc (NASDAQ: ADAG) announced clinical data on ADG116, and ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021. ADG116 monothe...

1 month ago - Benzinga

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pan...

Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab Additional highlights include pharmacodynami...

1 month ago - GlobeNewsWire

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumor...

- Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab - - Additional highlights include pharmaco...

1 month ago - GlobeNewsWire

Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

1 month ago - Zacks Investment Research

Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors

The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Investigational New Drug (IND) application to proceed with a Phase 1b/2 trial of ADG116, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrol...

1 month ago - Benzinga

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination ...

ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022 ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022

1 month ago - GlobeNewsWire

Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congr...

SAN DIEGO and SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discover...

1 month ago - GlobeNewsWire

Adagene to Participate in Upcoming Investor & Industry Conferences in November

SAN DIEGO and SUZHOU, China, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discover...

2 months ago - GlobeNewsWire

Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology...

- Presentations demonstrate compelling preclinical differentiation of an anti-CD47 antibody and a CD20xCD3 bispecific T-cell engager, both leveraging SAFEbody ™ technology -

2 months ago - GlobeNewsWire

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Sma...

- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium -

2 months ago - GlobeNewsWire

Adagene to Participate in the Jefferies Virtual China Biotech Summit

SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disc...

2 months ago - GlobeNewsWire

Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming...

4 months ago - GlobeNewsWire

Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

- Established three clinical collaborations with Merck to conduct global combination trials  with pembrolizumab for three clinical-stage oncology candidates -

4 months ago - GlobeNewsWire

Adagene Inks Third Cancer Trial Collaboration With Merck

Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansio...

Other symbols:MRK
4 months ago - Benzinga

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combina...

Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for patients with advanced or metastatic solid and/or hematological malignancies Collaboration to evaluate NEO...

4 months ago - GlobeNewsWire

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory B...

- Global immuno-oncology experts bring decades of experience to advance company's transformative research and development pipeline - - Global immuno-oncology experts bring decades of experience to advan...

5 months ago - GlobeNewsWire

Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors

Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  The agreement includes two clinical studies to evaluate Adagene's anti-C...

5 months ago - Benzinga

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (AD...

Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pembrolizumab) for patients with advanced/metastatic s...

5 months ago - GlobeNewsWire

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

SAN FRANCISCO and SUZHOU, China, July 07, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disc...

6 months ago - GlobeNewsWire

Adagene Announces Inclusion in FTSE Russell Indexes

SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) --  Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...

6 months ago - GlobeNewsWire

Adagene to Present at Upcoming Investor Conferences

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...

7 months ago - GlobeNewsWire

Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual ...

-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement

7 months ago - GlobeNewsWire